If you or a loved one is taking Tysabri, distinguishing early PML symptoms from other conditions is critical. For decades, medical research has established clear diagnostic criteria for progressive multifocal leukoencephalopathy, helping clinicians separate symptom patterns from confirmed disease. This page explains how symptoms relate to diagnosis and what the long-term outlook entails.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the John Cunningham virus (JCV). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing surveillance. The mechanism linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing latent JCV to reactivate and cause lytic infection of oligodendrocytes. The FDA label identifies three primary risk factors for PML: "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients with all three factors face the highest risk. The label further advises that "these factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML typically includes subacute neurological deficits such as cognitive decline, motor weakness, visual disturbances, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. The FDA label emphasizes that healthcare professionals "should monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these precautions, PML often progresses rapidly, leading to permanent disability or death.
The adequacy of warnings regarding Tysabri and PML is a central issue in legal contexts. The FDA's boxed warning is prominently placed in the prescribing information, and the drug is only available through the restricted TOUCH Prescribing Program, which requires patients to "read the Medication Guide, understand the risks associated with TYSABRI, and complete and sign the Patient Enrollment Form" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether prescribers adequately communicated these risks to patients, particularly regarding the cumulative nature of risk over time. The label notes that "the duration of treatment with TYSABRI prior to onset ranged from a few months to several years" for herpes infections, a similar opportunistic infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This timeline underscores that PML risk increases with prolonged exposure. For patients in North Carolina who developed PML after using Tysabri, attorney-related considerations include the statute of limitations for filing a product liability or medical malpractice claim. In North Carolina, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For PML, the timeline between exposure and documented harm can be complex. PML symptoms may emerge months to years after starting Tysabri, and diagnosis may be delayed due to nonspecific early signs. The FDA's adverse event reporting system (FAERS) lists common Tysabri-associated events such as "FATIGUE (19150 reports); MULTIPLE SCLEROSIS RELAPSE (16691 reports); HEADACHE (9626 reports); GAIT DISTURBANCE (9422 reports); MEMORY IMPAIRMENT (7895 reports); ASTHENIA (7852 reports)" (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These symptoms can mimic multiple sclerosis relapse, potentially delaying PML diagnosis. The discovery rule in North Carolina may allow the statute of limitations to begin when the patient or their representative knew, or should have known, that PML was caused by Tysabri. Given the severity of PML and the documented risk factors, affected patients should seek legal counsel promptly to assess their claim's timeliness. Evidence of inadequate warning or failure to monitor for PML symptoms could support a product liability action. The FDA label explicitly states that "TYSABRI increases the risk of PML" and that "when initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). If a physician did not adequately discuss these risks or failed to withhold Tysabri at the first sign of PML, liability may attach. In summary, the medical evidence clearly establishes that Tysabri increases PML risk, with identifiable risk factors and a need for vigilant monitoring. The legal landscape in North Carolina requires careful attention to the statute of limitations, which may be triggered by the date of diagnosis or discovery of causation. Patients and their families should consult an attorney experienced in pharmaceutical litigation to evaluate their options.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In North Carolina, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For PML, the discovery rule may allow the clock to start when the patient knew or should have known that PML was caused by Tysabri. Given the complexity, prompt legal consultation is advised.
Key evidence includes medical records documenting Tysabri use, PML diagnosis (MRI and JCV DNA test), and proof that the prescribing physician failed to adequately warn about PML risks or monitor for symptoms. The FDA boxed warning and TOUCH program requirements are central to establishing the standard of care.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.